スタチン以外の脂質療法における進歩:心血管疾患のリスクを減らすための進化戦略の記述的レビュー
Kayode Ogunniyi1,2, Chukwuemeka Christian Aghasili3, Olumide Akinmoju4
1Richmond University Medical Center/Mount Sinai, Staten Island, NY, USA.
まとめ
新しい非スタチンの治療法は コレステロールの目標に達できない患者や スタチンを我慢できない患者に代替手段を提供しています このレビューは,PCSK9阻害剤,ベンペド酸,および心血管疾患リスクに対する新興治療法を対象としています.
科学分野:
- 心臓病科
- 薬理学について
- 遺伝学
背景:
- スタチンの治療は,動脈硬化性心血管疾患 (ASCVD) のリスク低下に有益である.
- 多くの患者は目標の低密度脂質タンパク質コレステロール (LDL- C) を達成しないか,スタチン不耐性を経験する.
- 余剰ASCVDリスクを管理するには,代替の脂質低下戦略が不可欠です.
研究 の 目的:
- 現行および新興の非スタチンの脂質低下療法を見直す.
- 効果と安全性,および作用メカニズムを評価する.
- パーソナライズされた脂質管理の枠組みを提案し,実施の障壁について議論する.
主な方法:
- スタチン以外の脂質低下薬に関する画期的な臨床試験のレビュー
- 作用メカニズム,臨床有効性,安全性プロファイルの分析
- 新興治療法と実施課題の探索
主要な成果:
- プロプロテインコンバーターゼサブチリシン/ケキシン9型 (PCSK9) 阻害剤 (モノクローナル抗体,インクリシラン) とベンペド酸は,LDL- Cを有意に低下させています.
- 新興療法では,リポプロテイン (a),アポリポプロテインC-III,ANGPTL3,CETPなどの新しい経路を標的にし,遺伝子編集を使用しています.
- パーソナライズされた管理フレームワークと臨床的意思決定の経路が提案されています.
結論:
- スタチンの不耐性または不適切なLDL- C制御を有する患者にとって,スタチン以外の治療法は重要な選択肢です.
- 残留リスクと複雑な患者プロフィールに対処するために 個別化されたアプローチが必要である.
- 先進的な脂質減量戦略のグローバルな実施には,コストとアクセスの障壁を克服することが不可欠です.
関連する概念動画
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
865
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
865
01:26Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33
01:26Coronary Artery Disease IV: Preventive Measures
32
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
32
01:30Coronary Artery Disease I: Introduction
54
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
54
01:27Coronary Artery Disease V: Interprofessional Care
30
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
30
01:27Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29